Summary of ISSVA classification of vascular anomalies and review of literature in molecular biology

doi:10.19438/j.cjoms.2023.03.014

Abstract

Abstract: Vascular abnormalities are the general name of a group of diseases, which are divided into two categories by the International Society for the Study of Vascular Anomalies(ISSVA): vascular tumors and vascular malformations. In this paper, the latest research results of genetic changes in vascular diseases were summarized in combination with their molecular pathological manifestations. In glomuvenous malformations, the mutant globulin may activate PI3K signal through interaction with c-met. In addition, they may inhibit TGF-β-mediating smooth muscle cell differentiation and induce proliferation of so-called vascular globular cells. The mutation of PIK3CA in lymphatic malformation may stimulate the expression of VEGF-C or VEGFR3, induce the combination of PIK3CA with cell membrane, or increase cell proliferation, chemotaxis and angiogenesis by activating downstream Akt/mTOR. Mutation of RAS pathway in AVM may activate MEK/ERK signal, and RAS activation may induce morphological changes of endothelial cells, increase of budding behavior, expansion of vascular lumen, and abnormal connection between arteries and veins without cell proliferation. Mutation of VEGFR2 and TEM8 in infantile hemangioma leads to increased interaction between VEGFR2, TEM8 and integrin, and the resulting inactivation of integrin/NFATc2/VEGFR1 pathway may lead to phosphorylation of VEGFR2 and endothelial activation.

Key words: Venous malformation, Lymphatic malformation, Infantile hemangioma, Molecular biology

CLC Number:

R739.8

LI Xiao, FAN Xin-dong, ZHENG Jia-wei. Summary of ISSVA classification of vascular anomalies and review of literature in molecular biology[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(3): 286-290.

References

[1] 郑家伟, 赵泽亮. 婴幼儿血管瘤与脉管畸形的循证治疗研究进展[J]. 口腔疾病防治, 2021, 29(11): 721-732.
Zheng JW, Zhao ZL.Progress in evidencebased research on the clinical treatment of infantile hemangioma and vascular malformations[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(11): 721-732.
[2] Kunimoto K, Yamamoto Y, Jinnin M.ISSVA classification of vascular anomalies and molecular biology[J]. Int J Mol Sci, 2022, 23(4): 2358-2371.
[3] Castillo SD, Tzouanacou E, Zaw-Thin M, et al. Somatic activating mutations in PIK3CA cause sporadic venous malformations in mice and humans[J]. Sci Transl Med, 2016, 8(332): 332ra43.
[4] Castel P, Carmona FJ, Grego-Bessa J, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332): 332ra42.
[5] di Blasio L, Puliafito A, Gagliardi PA, et al. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations[J]. Cell Death Dis, 2018,9(2):45-60.
[6] Fereydooni A, Dardik A, Nassiri N.Molecular changes associated with vascular malformations[J]. J Vasc Surg, 2019, 70(1):314-326.
[7] Castillo SD, Baselga E, Graupera M.PIK3CA mutations in vascular malformations[J]. Curr Opin Hematol, 2019, 26(3):170-178.
[8] Blesinger H, Kaulfuβ S, Aung T, et al.PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J]. PLoS One,2018,13(7): e0200343.
[9] Couto JA, Huang AY, Konczyk DJ, et al.Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation[J]. Am J Hum Genet, 2017, 100(3): 546-554.
[10] Palmieri M, Currò A, Tommasi A, et al.Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation[J]. JVS Vasc Sci, 2020, 1: 176-180.
[11] Dekeuleneer V, Seront E, Van Damme A, et al.Theranostic advances in vascular malformations[J]. J Invest Dermatol, 2020, 140(4): 756-763.
[12] Smits PJ, Konczyk DJ, Sudduth, CL, et al.Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway[J]. Biochem Biophys Res Commun, 2020, 529(2): 450-454.
[13] Fish JE, Flores Suarez CP, Boudreau E, et al.Somatic gain of KRAS function in the endothelium is sufficient to cause vascular malformations that require MEK but not PI3K signaling[J]. Circ Res, 2020, 127(6): 727-743.
[14] Asadi S.The role of genetic mutations in gene GNAQ in Sturge-Weber syndrome[J]. Open Cell Sig J, 2019, 1(1): 14-18.
[15] Bichsel C, Bischoff J.A somatic missense mutation in GNAQ causes capillary malformation[J].Curr Opin Hematol, 2019, 26(3): 179-184.
[16] Nguyen V, Hochman M, Mihm MC, et al.The pathogenesis of port wine stain and sturge weber syndrome: complex interactions between genetic alterations and aberrant MAPK and PI3K activation[J]. Int J Mol Sci, 2019, 20(9): 2243-2260.
[17] 翟晓玥, 吴瑶, 娄寅,等. 趋化因子CXCL1在增殖期婴幼儿血管瘤组织中表达研究及外源性CXCL1对血管瘤干细胞的影响[J]. 安徽医科大学学报, 2022, 57(9): 1385-1388.
Zhai XY, Wu Y, Lou Y, et al.Study on the expression of chemokine CXCL1 in infantile hemangioma tissues and the effect of exogenous CXCL1 on hemangioma stem cells[J]. Acta Universitatis Medicinalis Anhui, 2022, 57(9): 1385-1388.
[18] Jinnin M, Ishihara T, Boye E, et al.Recent progress in studies of infantile hemangioma[J]. J Dermatol, 2010, 37(11): 283-298.
[19] Khan ZA, Melero-Martin JM, Wu X, et al.Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin[J].Blood, 2006,108(3): 915-921.
[20] Kleinman ME, Tepper OM, Capla JM, et al.Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma[J]. Lymphat Res Biol, 2003, 1(4): 301-307.
[21] Li HH, Lou Y, Zhang RR, et al.Propranolol accelerats hemangioma stem cell transformation into adipocyte[J]. Ann Plast Surg, 2019, 83(5): e5-e13.
[22] Melero-Martin JM, De Obaldia ME, Kang SY, et al.Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells[J]. Circ Res, 2008, 103(2): 194-202.
[23] Jinnin M, Medici D, Park L, et al.Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma[J]. Nat Med, 2008, 14(11): 1236-1246.
[24] Shibuya M, Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis[J]. Exp Cell Res, 2006, 312(5): 549-560.
[25] Kawaguchi A, Kunimoto K, Inaba Y, et al.Distribution analysis of infantile hemangioma or capillary malformation on the head and face in Japanese patients[J]. J Dermatol, 2019, 46(10): 849-852.
[26] Hashimoto A, Kunimoto K, Kawaguchi A, et al.Analysis of onset and clinical characteristics in Japanese patients with infantile hemangioma[J]. Drug Discov Ther, 2021, 15(4): 210-213.
[27] Lim YH, Bacchiocchi A, Qiu J, et al.GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation[J]. Am J Hum Genet, 2016, 99(2): 443-450.
[28] Lim YH, Fraile C, Antaya RJ, et al.Tufted angioma with associated Kasabach-Merritt phenomenon caused by somatic mutation in GNA14[J]. Pediatr Dermatol, 2019,36(6): 963-964.
[29] Ten Broek RW, Koelsche C, Eijkelenboom A, et al.Kaposiform hemangioendothelioma and tufted angioma-(epi)genetic analysis including genome-wide methylation profiling[J]. Ann Diagn Pathol, 2020,44: 151434.
[30] Venot Q, Blanc T, Rabia SH, et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018, 558(7711): 540-546.
[31] Freixo C, Ferreira V, Martins J, et al.Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review[J]. J Vasc Surg, 2020, 71(1): 318-327.
[32] Wang H, Guo X, Duan Y, et al.Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma[J]. Pediatr Dermatol, 2018, 35(5): 635-638.